attention deficiency hyperactivity disorder. Disturbance of activity and attention
Conditions
Interventions
Intervention 1: One group of patients are randomly assigned to the intervention group are treated with Memantine 10 mg. Therapeutic dosage of Memantine 10 mg is prescribed a tablet daily for the firs
in the second week, two tablets are daily prescribed (one in the morning at 8 o'clock, one at 14 o'clock)
if the weight is above 30 pounds, 3 tablets will be daily prescribed in the second week (one and a half tablet each morning at 8 o'clock, one and a half tablet at 14 o'clock).
Treatment - Drugs
One group of patients are randomly assigned to the intervention group are treated with Memantine 10 mg. Therapeutic dosage of Memantine 10 mg is prescribed a tablet daily for the first week (half tab
if the weight is above 30 pounds, 3 tablets will be daily prescribed in the second week (one and a half tablet each morning at 8 o'clock, one and a half tablet at 14 o'clock)
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
6 Years to 11 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: receiving DSM-IV-TR diagnostic criteria for ADHD; the age range of 6 to 11 years old; not using any psychiatric drugs at least 2 weeks before the research. Exclusion criteria: having mental retardation; having any psychiatric disorders except ODD; allergic history to Memantine; having serious disorder like heart disease; uncontrolled Seizure disorder; individuals with Systolic blood pressure above 125 mmHg or resting pulse under 60 or having above 115 beats per minute.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The ADHD symptoms. Timepoint: Baseline, third and sixth weeks after intervention. Method of measurement: ADHD Rating Scale, Clinical Global Impressions Severity. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects. Timepoint: Baseline, third and sixth weeks after intervention. Method of measurement: Side effects quesionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSoleiman Mohammadzadeh, MD
Tehran University of Medical Sciences, Psychiatry research center
Outcome results
None listed